X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (191) 191
oncology (168) 168
male (160) 160
middle aged (142) 142
aged (134) 134
index medicus (121) 121
female (115) 115
adult (111) 111
prognosis (88) 88
aged, 80 and over (63) 63
vdp (62) 62
cancer (60) 60
medical disciplines: 700 (57) 57
medisinske fag: 700 (57) 57
survival (55) 55
lung neoplasms - pathology (54) 54
oncology: 762 (54) 54
clinical medical disciplines: 750 (53) 53
vdp::medical disciplines: 700::clinical medical disciplines: 750::oncology: 762 (52) 52
klinisk medisinske fag: 750 (51) 51
carcinoma, non-small-cell lung - pathology (50) 50
onkologi: 762 (50) 50
vdp::medisinske fag: 700::klinisk medisinske fag: 750::onkologi: 762 (50) 50
chemotherapy (49) 49
neoplasm staging (47) 47
lung cancer (44) 44
tumors (44) 44
nsclc (40) 40
medicine (38) 38
expression (37) 37
immunohistochemistry (37) 37
lung neoplasms - mortality (37) 37
carcinoma (35) 35
follow-up studies (34) 34
lung cancer, non-small cell (33) 33
respiratory system (32) 32
carcinoma, non-small-cell lung - mortality (30) 30
research article (30) 30
research (28) 28
survival rate (28) 28
treatment outcome (28) 28
analysis (27) 27
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
survival analysis (27) 27
adolescent (26) 26
retrospective studies (26) 26
pathology (25) 25
risk factors (25) 25
angiogenesis (24) 24
metastasis (24) 24
multidisciplinary sciences (24) 24
radiotherapy (24) 24
multivariate analysis (23) 23
norway - epidemiology (23) 23
lung neoplasms - metabolism (22) 22
biomarkers, tumor - metabolism (21) 21
care and treatment (21) 21
hematology, oncology and palliative medicine (21) 21
lung neoplasms - drug therapy (21) 21
quality of life (21) 21
disease-free survival (20) 20
hospitals (20) 20
science (20) 20
surveys and questionnaires (20) 20
tissue array analysis (20) 20
patients (19) 19
prostate cancer (19) 19
testicular cancer (19) 19
carcinoma, non-small-cell lung - metabolism (18) 18
testicular neoplasms - therapy (18) 18
animals (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
carcinoma, non-small-cell lung - genetics (17) 17
cisplatin (17) 17
impact (17) 17
norway (17) 17
proteins (17) 17
studies (17) 17
biology (16) 16
breast-cancer (16) 16
lung neoplasms - genetics (16) 16
non-small cell lung cancer (16) 16
quality-of-life (16) 16
young adult (16) 16
clinical medicine (15) 15
cross-sectional studies (15) 15
endothelial growth-factor (15) 15
medical prognosis (15) 15
time factors (15) 15
non-small cell lung carcinoma (14) 14
carboplatin - administration & dosage (13) 13
carcinoma, non-small-cell lung - drug therapy (13) 13
cell lung-cancer (13) 13
combined modality therapy (13) 13
diagnosis (13) 13
gene expression (13) 13
lung neoplasms - radiotherapy (13) 13
prognostic impact (13) 13
stroma (13) 13
stromal cells (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


British Journal of Cancer, ISSN 0007-0920, 10/2006, Volume 95, Issue 8, pp. 966 - 973
This randomised multicentre trial was conducted to establish the optimal duration of palliative chemotherapy in advanced non-small-cell lung cancer (NSCLC). We... 
Non-small-cell lung cancer | Chemotherapy | Treatment duration | Survival | Palliative | Quality of life | PLUS CHEMOTHERAPY | CARBOPLATIN | SUPPORTIVE CARE BSC | METAANALYSIS | palliative | QUESTIONNAIRE QLQ-C30 | VINORELBINE | survival | RANDOMIZED-TRIAL | chemotherapy | treatment duration | PHASE-III TRIAL | ONCOLOGY | CLINICAL-TRIALS | quality of life | ELDERLY-PATIENTS | non-small-cell lung cancer | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Palliative Care | Fatigue - chemically induced | Pain - chemically induced | Vinblastine - administration & dosage | Carboplatin - adverse effects | Time Factors | Vinblastine - analogs & derivatives | Vinblastine - adverse effects | Aged, 80 and over | Adult | Female | Surveys and Questionnaires | Carcinoma, Non-Small-Cell Lung - pathology | Drug Administration Schedule | Carboplatin - administration & dosage | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Clinical Studies | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
by Ou, S. I and Camidge, D. R and Engelman, J and Clark, J and Tye, L and Wilner, K and Stephenson, P and Varella-Garcia, M and Iafrate, A and Shaw, A. T and Hainaut, P and Ma, X and Lacas, B and Tsao, M and Douillard, J and Rousseau, V and Dunant, A and Seymour, L and Filipits, M and Graziano, S and He, J and Yang, H and Deng, Q and He, P and Jiang, J and Zhao, M and Gu, X and Zheng, L and Pang, H and Zhou, J. X and Reinmuth, N and Scherer, S. J and Penzel, R and Schnabel, P and Meister, M and Kiemle-Kallee, J and Reuss, A and Fischer, J. R and Wolf, M and Thomas, M and von Laffert, M and Berg, E and Lenze, D and Lohneis, P and Hummel, M and Dietel, M and Han, X and Ma, L and Liu, Y and Zhang, N. N and Li, D and Shi, Y and Furugaki, K and Iwai, T and Moriya, Y and Fujimoto-Ouchi, K and Mok, T. S. K and Park, K and Geater, S. L and Agarwal, S and Han, M and Credi, M and McKee, K and Kuriyama, N and Slichenmyer, W and Tan, E. H and Greillier, L and Martel-Lafay, I and Arpin, D and Pourel, N and Chabaud, S and Lamy, R and Madroszyk, A and Fournel, P and Strom, H. H and Sundstrom, S and Helbekkmo, N and Bremnes, R and Aasebo, U and van Elmpt, W and Ollers, M and Dingemans, A. C and Lambin, P and De Ruysscher, D and Topkan, E and Parlak, C and Topuk, S and Ozyilkan, O and Uyterlinde, W and Vincent, A. D and Belderbos, J and Korse, T and Baas, P and van den Heuvel, M and Satouchi, M and Chiba, Y and Yamamoto, N and Nishimura, Y and Tsujino, K and Fujisaka, Y and ... and on behalf of The Mar-LC Collaborative Group
Annals of Oncology, ISSN 0923-7534, 09/2012, Volume 23, Issue suppl 9, pp. ix389 - ix399
Journal Article
Annals of Oncology, ISSN 0923-7534, 2007, Volume 18, Issue 2, pp. 241 - 248
Journal Article
SCIENTIFIC REPORTS, ISSN 2045-2322, 07/2019, Volume 9, Issue 1, pp. 10662 - 10
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2009, Volume 101, Issue 24, pp. 1682 - 1695
Background Sensory neuropathy (paresthesias), tinnitus, hearing impairment, and Raynaud phenomena are side effects of cisplatin-based chemotherapy used to... 
CISPLATIN-BASED CHEMOTHERAPY | HEARING-LOSS | RISK-FACTORS | ONCOLOGY | EUROPEAN CONSENSUS CONFERENCE | CLINICAL STAGE-I | INDUCED PERIPHERAL NEUROPATHY | COMBINATION CHEMOTHERAPY | QUALITY-OF-LIFE | GERM-CELL-CANCER | MEDICAL-RESEARCH-COUNCIL | Paresthesia - epidemiology | Sensation Disorders - epidemiology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prevalence | Audiometry | Follow-Up Studies | Humans | Middle Aged | Survivors - statistics & numerical data | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cisplatin - administration & dosage | Raynaud Disease - epidemiology | Tinnitus - chemically induced | Adult | Surveys and Questionnaires | Odds Ratio | Paresthesia - chemically induced | Hearing Loss - chemically induced | Severity of Illness Index | Sensation Disorders - chemically induced | Cross-Sectional Studies | Drug Administration Schedule | Seminoma - drug therapy | Hearing Loss - epidemiology | Regression Analysis | Tinnitus - epidemiology | Testicular Neoplasms - drug therapy | Norway - epidemiology | Cisplatin - adverse effects | Raynaud Disease - chemically induced | Aged | Research Design | Cancer survivors | Complications and side effects | Prognosis | Demographic aspects | Raynaud's disease | Testicular cancer | Peripheral nerve diseases | Risk factors | Diseases | Index Medicus
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 10/2008, Volume 99, Issue 9, pp. 1476 - 1483
Vimentin, nuclear factor-kappa B (NF-kappa B) p105, fascin, E-cadherin, TGF-beta, Par6 and atypical PKC are molecular markers that play an important role in... 
Par6 | Vimentin | Stromal | NSCLC | Disease-specific survival | Epithelial | par6 | stromal | METASTASIS | TUMOR PROGRESSION | epithelial | KERATINOCYTES | vimentin | MESENCHYMAL TRANSITION | HORMONE RECEPTORS | BETA | OVEREXPRESSION | disease-specific survival | ONCOLOGY | POLARITY PROTEIN PAR6 | DIFFERENTIATION | CARCINOMA | Molecular Diagnostics
Journal Article
Annals of Oncology, ISSN 0923-7534, 09/2003, Volume 14, Issue 9, pp. 1399 - 1405
Journal Article
Journal Article